Dr. Reddy's Laboratories Ltd Common Stock (RDY)

Cost of Revenue

₹43.42B

Quarterly · Period ending: · INR

RDY logo

RDY Cost of Revenue

Latest reported₹43.42B INR
RDY Quarterly Cost of Revenue · INR (₹1.57B → ₹43.42B)
High-resolution chart · PNG

RDY cost of revenue history

Quarterly · INR. Dates are reporting period ends; fiscal years can differ from calendar years.

Dr. Reddy's Laboratories Ltd Common Stock Cost of Revenue — Quarterly (INR)
Period endingCost of Revenue (INR)
43,421,071,000
42,116,218,000
40,462,000,000
39,911,000,000
36,825,000,000
37,797,000,000
34,534,000,000
32,393,000,000
30,383,000,000
29,347,000,000
29,945,000,000
363,253,991
27,831,000,000
327,926,720
27,607,000,000
323,400,757
26,148,000,000
340,573,093
24,585,000,000
362,339,094
23,495,000,000
300,562,704
22,758,000,000
326,429,490
19,420,000,000
21,510,000,000
303,127,655
20,389,000,000
18,576,000,000
19,113,000,000
17,748,000,000
17,081,000,000
16,479,000,000
16,454,000,000
16,649,000,000
16,559,000,000
16,062,000,000
17,360,000,000
15,166,000,000
15,760,000,000
14,167,000,000
16,286,000,000
16,089,000,000
15,421,000,000
14,631,000,000
17,483,000,000
16,079,000,000
14,893,000,000
14,331,000,000
14,887,000,000
13,947,000,000
14,106,000,000
13,430,000,000
16,554,000,000
13,560,000,000
13,504,000,000
11,865,000,000
12,613,000,000
11,117,000,000
10,473,000,000
9,228,000,000
9,224,000,000
8,571,000,000
8,718,000,000
7,917,000,000
7,785,000,000
8,487,000,000
9,649,000,000
8,017,000,000
9,082,000,000
8,129,000,000
8,187,444,000
7,475,000,000
6,211,857,528
6,290,893,149
6,030,510,165
5,925,152,821
5,825,441,892
8,713,130,958
11,710,148,485
7,974,268,705
4,072,145,379
2,909,270,955
2,779,526,054
2,662,869,511
2,778,981,417
2,069,478,219
2,440,229,377
2,481,655,091
2,286,743,252
2,463,789,929
2,459,816,912
2,171,674,516
1,539,756,345
1,983,980,786
2,283,478,320
2,019,734,813
1,673,059,760
1,811,662,609
1,812,913,125
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.